Nasus Pharma Ltd. (NSRX)
| Market Cap | 72.08M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.53M |
| Shares Out | 9.01M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About NSRX
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active powder-based intranasal technology, or PBI, specialized products. To help achieve this we are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and an... [Read more]
News
Nasus Pharma Announces Pricing of $10 Million Initial Public Offering
TEL AVIV, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative i...
Nasus Pharma IPO Shows Promise But Risks Remain
Nasus Pharma is developing a needle-free intranasal epinephrine spray for severe allergies, showing promising but early trial results in a small population. The company is thinly capitalized, faces a ...
Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO
Nasus Pharma, a Phase 2 biotech developing an intranasal powder for severe allergies and anaphylaxis, filed on Wednesday with the SEC to raise up to $11 million in an initial public offering.
Nasus Pharma IPO Registration Document (F-1)
Nasus Pharma has filed to go public with an IPO on the NYSE American.